Highlighted Publications 2023
Highlighted Publications 2024
Highlighted Publications 2025
Results from Previous Trials
Highlighted Publications 2023
| CLEAR Outcomes Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. |
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE. New England Journal of Medicine. 2023 Apr 13;388(15):1353-64. https://www.nejm.org/doi/full/10.1056/NEJMoa2215024 |
| CLEAR Outcomes Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. |
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJ, Cho L, Libby P, Na Li, PhD6; JoAnne Foody, MD6; Michael J. Louie, MD, MPH, MSc6; A. Michael Lincoff, MD, JAMA. 2023; 330(2):131-140 |
| CLEAR Outcomes Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. |
Kausik K Ray FMedSci, Stephen J Nicholls, PhD, Na Li, PhD, Michael J Louie, MD, Danielle Brennan, MS, A. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00316-9/fulltext |
| CLEAR Outcomes Background ezetimibe use among participants in the CLEAR Outcomes trial. |
Luke J. Laffin, Danielle Brennan, LeAnne Bloedon, Na Li, Steven E. Nissen. American Journal of Preventive Cardiology, Volume 15, Supplement, September 2023, 100551. https://www.sciencedirect.com/science/article/ pii/S2666667723000922 Michael Lincoff, MD, Steven E. Nissen, MD. Submitted to Lancet Diabetes |
| CLEAR Outcomes Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance. |
Paul M. Ridker, Lei Lei, Michael J. Louie, Tariq Haddad, Stephen J. Nicholls, A. Michael Lincoff, Peter Libby and Steven E. Nissen. 2023. https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066213 |
| ELEKT-D Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. |
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA. New England Journal of Medicine. 2023 Jun 22;388(25):2315-25. https://www.nejm.org/doi/full/10.1056/NEJMoa2302399 |
| TRAVERSE Cardiovascular Safety of Testosterone-Replacement Therapy. |
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson Jr IM, Wang Q. New England Journal of Medicine. 2023 Jun 16. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025 |
| TRAVERSE Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. |
Pencina KM, Travison TG, Cunningham GR, Lincoff AM, Nissen SE, Khera M, Miller MG, Flevaris P, Li X, Wannemuehler K, Bhasin S. J Clin Endocrinol Metab. 2023 Aug 17:dgad484. doi: 10.1210/clinem/dgad484 |
| TRAVERSE Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism. A Randomized Clinical Trial. |
Karol M. Pencina, PhD; Thomas G. Travison, PhD; Andrew S. Artz, MD, MS; A. Michael Lincoff, MD4; Steven E. Nissen, MD; Panagiotis Flevaris, MD, PhD; Anna Chan, PharmD; Xue Li, PhD; Scott A. Diegel, MS; Kathleen Wannemuehler, PhD; Shalender Bhasin, MB, BS. JAMA Netw Open. 2023;6(10):e2340030. . https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2811115 |
| TRAVERSE Testosterone Treatment and Fractures in Men with Hypogonadism. |
Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. N Engl J Med. 2024 Jan 18;390(3):203-211. doi: 10.1056/NEJMoa2308836. PMID: 38231621. https://www.nejm.org/doi/10.1056/NEJMoa2308836 |
| Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. | Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE; for the PROMINENT, REDUCE-IT, and STRENGTH Investigators. The Lancet. 2023 Apr 15;401(10384):1293-301. https://www.thelancet.com/journals/lancet/article/ PIIS0140-6736(23)00215-5/fulltext |
| VALOR Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks. |
Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, Sherrid M, Cremer PC, Naidu SS, Smedira NG, Schaff H. Circulation. 2023 Mar 14;147(11):850-63. https://www.ahajournals.org/doi/epub/10.1161/ CIRCULATIONAHA.122.062534 |
| VALOR Improvement in Multi-Domain Patient-Reported Outcome Scores with Mavacamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Insight from the VALOR-HCM Study. |
Desai MY, Spertus JA, Owens AT, Geske JB, Wolski K, Saberi S, Wang A, Sherrid MV, Cremer P, Lakdawala NK, Fifer MA. Journal of the American College of Cardiology. 2023 Mar 7;81(8_Supplement):323-. https://www.jacc.org/doi/10.1016/S0735-1097%2823%2900767-2 |
| VALOR Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. |
Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D. JAMA cardiology. 2023 Aug 28. https://jamanetwork.com/journals/jamacardiology/article-abstract/2809050#:~:text=Findings%20Results%20of%20A%20Study,56%2C%205%20of%2056%20patients%20 |
| VALOR-HCM Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction Week 56 Results From the VALOR-HCM Randomized Clinical Trial. |
Milind Y. Desai, MD, MBA; Anjali Owens, MD; Kathy Wolski, MPH; Jeffrey B. Geske, MD; Sara Saberi, MD, MS; Andrew Wang, MD; Mark Sherrid, MD; Paul C. Cremer, MD, MS; Neal K. Lakdawala, MD; Albree Tower-Rader, MD; David Fermin, MD; Srihari S. Naidu, MD; Nicholas G. Smedira, MD, MBA; Hartzell Schaff, MD; Ellen McErlean, RN, MSN; Christina Sewell, RN; Lana Mudarris, PharmD; Zhiqun Gong, MS; Kathy Lampl, MD; Amy J. Sehnert, MD; Steven E. Nissen, MD. JAMA Cardiol. 2023;8(10):968-977. doi:10.1001/jamacardio.2023.3342. https://jamanetwork.com/journals/jamacardiology/article-abstract/2809050 |
| TARGET-HTN Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension. The Target-HTN Randomized Clinical Trial. |
Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, Slingsby BT, Nissen SE; for the Target-HTN Investigators. JAMA.2023;330(12):1140-1150.doi:10.1001/jama.2023.16029 |
| Coronary atheroma regression with evolocumab in stable and unstable coronary syndromes. Cardiovascular Imaging. | Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JP, Hermanides RS, Wang B. 2023 Jan 1;16(1):130-2. https://www.jacc.org/doi/10.1016/j.jcmg.2022.07.020 |
| Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. | Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF. 2023Aug28:e2316503.doi: 10.1001/jama.2023.16503. |
| Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. | Prof Paul M Ridker, MD , Prof Deepak L Bhatt, MD, Aruna D Pradhan, MD, Prof Robert J Glynn, ScD, Jean G MacFadyen, BA, Prof Steven E Nissen, MD; on behalf of the PROMINENT, REDUCE-IT, and STRENGTH Investigators. VOLUME 401, ISSUE 10384, P1293-1301, APRIL 15, 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00215-5/fulltext |
| SPORT Are dietary supplements beneficial in lowering cholesterol? SPORT reflections and the path forward. |
Luke J Laffin, Dennis Bruemmer, Steven E Nissen. European Heart Journal, Volume 44, Issue 8, 21 February 2023, Pages 638–640, https://doi.org/10.1093/eurheartj/ehac729. |
| Global Cardio Oncology Registry (G-COR) Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative. |
Arco J. Teske, Rohit Moudgil, Teresa López-Fernández, Ana Barac, Sherry Ann Brown, Anita Deswal, Tomas G. Neilan, Sarju Ganatra, Husam Abdel Qadir, Venu Menon, Aaron L. Sverdlov, Richard K. Cheng, Silvia Makhoul, Arjun K. Ghosh, Sebastian Szmit, Vlad Zaha, Daniel Addison, Lili Zhang, Joerg Herrmann, Jun H. Chong, Vivek Agarwala, Zaza Iakobishvili, Patricia Guerrero, Eric H. Yang, Monika Leja, Nausheen Akhter, Avirup Guha, Tochukwu M. Okwuosa, Carolina Carvalho Silva, Patrick Collier, Jeanne DeCara, Brenton Bauer, Carrie E. Lenneman and Diego Sadler. Originally published13 Sep 2023. Circulation: Cardiovascular quality and Outcomes, Volume 16, Number 10 |
| WATCH-TAVR Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement (WATCH-TAVR Study) |
Samir R. Kapadia, MD; Amar Krishnaswamy, MD; Brian Whisenant, MD; Srinivasa Potluri, MD, Vijay Iyer, MD; Joseph Aragon, MD; Philip Gideon, MD; Justin Strote, MD; Robert Leonardi, MD; Himanshu Agarwal, MD; German Larrain, MD; Carlos Sanchez, MD; Sidakpal S. Panaich, MD, James Harvey, MD; Torsten Vahl, MD; Venu Menon, MD; Kathy Wolski, MS, Qiuqing Wang, MS, Martin B. Leon12, MD. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067312 |
| Lepodisiran Phase 1 A Phase 1 Single Ascending Dose Trial of an Extended Duration Short-interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. |
Steven E. Nissen, MD, Helle Linnebjerg PhD, Xi Shen PhD, Kathy Wolski, MPH, Xiaosu Ma, PhD, Shufen Lim PhD, Laura F. Michael PhD, Giacomo Ruotolo, MD, PhD, Grace Gribble MS, Ann Marie Navar MD, and Stephen J. Nicholls, MBBS, PhD. JAMA. Published online November 12, 2023. doi:10.1001/jama.2023.21835 https://jamanetwork.com/journals/jama/fullarticle/2811935 |
| Association of pulse pressure with risk of major adverse cardiovascular events among cardiovascular outcome trial participants. | N Agarwal, J St Jean, E H Van Iterson, L Laffin. European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.2317, https://doi.org/10.1093/eurheartj/ehad655.2317. https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.2317/7393132 |
Highlighted Publications 2024
| Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial | Steven E. Nissen, Kathy Wolski, Gerald F. Watts, Michael J. Koren, Henry Fok, Stephen J. Nicholls, David A. Rider, Leslie Cho, Steven Romano, Carrie Melgaard, Curtis Rambaran |
| CLEAR Outcomes- (secondary pub) Impact of Bempedoic Acid on Total Cardiovascular Events A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. |
Stephen J. Nicholls, MBBS, PhD; Adam J. Nelson, MBBS, PhD; A. Michael Lincoff, MD; Danielle Brennan, MS; Kausik K. Ray, MD, MPhil; Leslie Cho, MD; Venu Menon, MD; Na Li, PhD; LeAnne Bloedon, MS; Steven E. Nissen, MD. JAMA Cardiol. January 17, 2024. doi:10.1001/jamacardio.2023.5155 https://jamanetwork.com/journals/jamacardiology/article-abstract/2813647 |
| TRAVERSE – (secondary pub) Testosterone Treatment and Fractures in Men with Hypogonadism. |
Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. N Engl J Med. 2024 Jan 18;390(3):203-211. doi:10.1056/NEJMoa2308836. PMID: 38231621 https://www.nejm.org/doi/10.1056/NEJMoa2308836 |
| Male Sex is Associated with Worse Right Ventricular Function and Survival in Pulmonary Hypertension in the PVDOMICS Cohort. | Nicholas J. Shelburne, Hui Nian, Gerald J. Beck, Nancy G. Casanova, Ankit A. Desai, Hilary M. DuBrock, Serpil Erzurum, Robert P. Frantz, Paul M. Hassoun, Nicholas S. Hill, Evelyn M. Horn, Miriam S. Jacob, Christine L. Jellis, Elizabeth Joseloff, Deborah H. Kwon, A. Brett Larive, Jane A. Leopold, Margaret M. Park, Franz P. Rischard, Erika B. Rosenzweig, Rebecca R. Vanderpool, Chang Yu, Anna R. Hemnes, and the PVDOMICS Study Group. 15 February 2024 https://doi.org/10.1016/j.chpulm.2024.100046https://www.chestpulmonary.org/article/S2949-7892(24)00012-6/pdf |
|
AEGIS-II |
C. Michael Gibson, MD, Danielle Duffy, MD, Serge Korjian, MD, M. Cecilia Bahit, MD, Gerald Chi, MD, John H. Alexander, MD, MHS, A. Michael Lincoff, MD for the AEGIS-II Committees and Investigators. |
| TACTiC A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication |
Steven E. Nissen, Howard G. Hutchinson, Kathy Wolski, Karol Watson, Seth S. Martin, Erin D. Michos, William S. Weintraub, Melanie Morris, Leslie Cho, Luke Laffin, Douglas Jacoby, Christie M. Ballantyne, Jan Ekelund, Filip Birve, Venu Menon, Michelle Strzelecki, and Paul M. Ridker J Am Coll Cardiol. Apr 08, 2024 |
|
CSL300_2301 Phase 2b publication, Clazakizumab |
Glenn M. Chertow, Anna Marie Chang, G. Michael Felker, Mark Heise, Elena Velkoska, Bengt Fellström, David M. Charytan, Regina Clementi, C. Michael Gibson, Shaun G. Goodman, Meg Jardine, Adeera Levin, Yuliya Lokhnygina, Jenny Mears, Roxana Mehran, Peter Stenvinkel, Angela Wang, David C. Wheeler, Carmine Zoccali, Paul M. Ridker, Kenneth W. Mahaffey, Pierluigi Tricoci & Myles Wolf. Nature Medicine 30,2328-2336, (2024). |
|
VALOR-HCM |
Milind Y Desai, Anjali Owens, Kathy Wolski, Jeffrey B Geske, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C Cremer, Neal K Lakdawala, Albree Tower-Rader, David Fermin, Srihari S Naidu, Nicholas G Smedira, Hartzell Schaff, Ellen McErlean, Christina Sewell, Yue Zhong, Kathleen W Wyrwich, Kathy L Lampl, Amy J Sehnert, Steven E Nissen, John A Spertus; VALOR-HCM InvestigatorsJ Am Coll Cardiol.202410;84(11):1041-1045. |
| CLEAR Outcomes Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial |
Abhayjit Singh , Luke J Laffin, Ashish Sarraju, A Michael Lincoff, Stephen J Nicholls, LeAnne Bloedon, William J Sasiela, Na Li, Paula Robinson, Stephanie Kelly, Denise Mason, Steven E Nissen. Clin Cardiol 2024 Aug;47(8):e24328. |
| Design and Rationale of the V-Wave Shunt MitraClip Study |
Grant W Reed, Evan K Harmon, Serge Harb, James Yun, Amar Krishnaswamy, William T Abraham, Samir Kapadia Am J Cardiol 2024 Sep 15:227:29-36. |
| Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity |
Milton Packer, M.D., Michael R. Zile, M.D., Christopher M. Kramer, M.D., Seth J. Baum, M.D., Sheldon E. Litwin, M.D., Venu Menon, M.D., Junbo Ge, M.D., +6, for the SUMMIT Trial Study Group |
Highlighted Publications 2025
| Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM | Milind Y. Desai, MD, MBA, Yuichiro Okushi, MD, Kathy Wolski, MPH, Jeffrey B. Geske, MD, Anjali Owens, MD, Sara Saberi, MD, MS, Andrew Wang, MD, Paul C. Cremer, MD, MS, Mark Sherrid, MD, Neal K. Lakdawala, MD, Albree Tower-Rader, MD, David Fermin, MD, Srihari S. Naidu, MD, Kathy L. Lampl, MD, Amy J. Sehnert, MD, Steven E. Nissen, MD, Zoran B. Popovic, MD, PHD, the VALOR-HCM Investigators JACC: CARDIOVASCULAR IMAGING, VOL. 18, NO. 3, 2025 https://www.sciencedirect.com/science/article/pii/S1936878X24003450?via%3Dihub |
| Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | Steven E. Nissen, M.D., Wei Ni, Ph.D., Xi Shen, Ph.D., Qiuqing Wang, M.S., Ann Marie Navar, M.D., Ph.D., Stephen J. Nicholls, M.B., B.S., Ph.D., Kathy Wolski, M.P.H., Laura Michael, Ph.D., Axel Haupt, M.D., and John H. Krege, M.D., for the ALPACA Trial Investigators. N Engl J Med 2025;392:1673-1683, VOL. 392, NO.1 Published March 30, 2025 https://www.nejm.org/doi/full/10.1056/NEJMoa2415818 |
| Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension |
L.J. Laffin, B. Kopjar, C. Melgaard, K. Wolski, J. Ibbitson, S. Bhikam, M.R. Weir, E.O. Ofili, R. Mehra, J.M. Luther, D.L. Cohen, A. Sarraju, M.J. Wilkinson, J.M. Flack, D. Rodman, and S.E. Nissen, for the Advance-HTN Investigators |
|
Fixed-dose Combination of Obicetrapib and Ezetimibe |
Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, Amanda Stronczek, Anne C Goldberg, Erin D Michos, Darren K McGuire, Denise Mason, Grace Tercek, Stephen J Nicholls, Douglas Kling, Annie L Neild, John Kastelein, Michael Davidson, Marc Ditmarsch, Steven E Nissen Lancet, 2025 May 17;405(10491):1757-1768. https://pubmed.ncbi.nlm.nih.gov/40347969/ |
|
Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Genotype Status: Insights From VALOR-HCM TRIAL |
Milind Y. Desai, Anjali Tiku Owens, Sara Saberi, Andrew Wang, Kathy Wolski, Paul Cremer, Neal K. Lakdawala, Albree Tower Rader, Mark A. Zenker, Mark V. Sherrid, Jeffrey Benjamin Geske, David R. Fermin, Srihari S. Naidu, Kathy Lampl, Amy Sehnert, On behalf of VALOR-HCM, investigators, and Steven E. Nissen JACC. 2025 Apr, 85 (12_Supplement) 1245. https://www.sciencedirect.com/science/article/pii/S0735109725017292?via%3Dihub |
Results from Previous Trials
Cardiovascular Outcomes
| ACCELERATE | Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease | 2017 | NEJM | Primary |
| ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease a nested case-control study | 2018 | JAMA | Secondary | |
| Elevated Levels of the Neutrophil to Lymphocyte Ratio Predicts Incidence of Major Adverse Cardiovascular Events in High Risk Patients: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Gender Specific Factors Associated with Major Cardiovascular Events: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Prior Cornoary Artery Bypass Grafting and Incident Cardiovascular Events in the Setting of Contemporary Medical Therapy: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial | 2019 | Diab Vasc Dis Res | Secondary | |
| Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy | 2019 | JAHA | Secondary | |
| Plasma aldosterone levels are not associated with cardiovascular events among patients with high-risk vascular disease: Insights from the ACCELERATE trial | 2019 | JAHA | Secondary | |
| The role of lipoprotein (a) as a marker of residual risk in patients with diabetes and established cardiovascular disease on optimal medical therapy: a post-hoc analysis of ACCELERATE | 2019 | Diabetes Care | Secondary | |
| PRECISION | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis | 2016 | NEJM | Primary |
| Cardiorenal Risks of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: A Sub-Analysis From The PRECISION trial | 2017 | EHJ | Secondary | |
| Differential Blood Pressure Effects of Ibuprofen, Naproxen and Celecoxib in Patients with Arthritis: The PRECISION - ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial | 2017 | EHJ | Secondary | |
| Gastrointestinal Events in Arthritis Patients at Increased Cardiovascular Risk Treated Chronically with Celecoxib, Naproxen or Ibuprofen: the PRECISION Randomized Controlled Trial | 2017 | Gastroenterology | Secondary | |
| The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen or Naproxen: A Secondary Analysis of the PRECISION Randomized Controlled Clinical Trial | 2017 | Am J Med | Secondary | |
| Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial | 2018 | AJG | Secondary | |
| Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen | 2018 | JACC | Secondary | |
| Gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial | 2018 | AP&T | Secondary | |
| The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: A secondary analysis of the PRECISION trial | 2018 | Rheumatology | Secondary | |
| LIGHT | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. A Randomized Clinical Trial | 2016 | JAMA | Primary |
| VISTA-16 | Varespladib and Cardiovascular Events in Patients With an Acute Coronary SyndromeThe VISTA-16 Randomized Clinical Trial | 2014 | JAMA | Primary |
| Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. A Secondary Analysis of the VISTA-16 Trial | 2019 | JAMA Cardiol | Secondary | |
| dal – Outcomes | Effects of dalcetrapib in patients with a recent acute coronary syndrome | 2012 | NEJM | Primary |
| TRACER | Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes | 2012 | NEJM | Primary |
Thrombin Inhibition
| CHOOSE - ON | Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial | 2014 | Ann Thorac Surg | Primary |
Atherosclerosis Progression
| SATURN | Effect of two intensive statin regimens on progression of coronary disease | 2011 | NEJM | Primary |
| Factors underlying regression of coronary atheroma with potent statin therapy | 2013 | EHJ | Secondary | |
| Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN | 2014 | EHJ | Secondary | |
| Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN | 2017 | Atherosclerosis | Secondary | |
| Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN | 2017 | Atherosclerosis | Secondary | |
| GLAGOV | Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsThe GLAGOV Randomized Clinical Trial | 2016 | JAMA | Primary |
| Effect of Evolocumab on Coronary Plaque Composition | 2018 | JACC | Secondary | |
| Elevated CRP Levels do not Adversely Modulate the Ability of Evolucumab to Regress Coronary Atherosclerosis: Insights from GLAGOV | 2018 | JACC | Secondary | |
| Greater Likelihood of Regression of Coronary Atherosclerosis with the PCSK9 Inhibitor, Evolcumab, in Patients with Higher Lp(a) Levels | 2018 | JACC | Secondary | |
| Levels of Non-High-Density Lipoprotein Cholesterol do not Negatively Impact the Ability of the PCSK9 Inhibitor, Evolucumab, to Promote Regression of Coronary Atherosclerosis | 2018 | JACC | Secondary | |
| Sex-Related Difference in the Regression of Coronary Atherosclerosis with the PCSK9 Inhibitor, Evolucumab: Insights from GLAGOV | 2018 | JACC | Secondary | |
| GAUSS-3 | Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceThe GAUSS-3 Randomized Clinical Trial | 2016 | JAMA | Primary |
| ASSURE | Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial | 2015 | Am J Card Drugs | Primary |
| MILANO PILOT | Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein a-i milano on coronary disease in patients with an acute coronary syndrome in the milano-pilot trial: A randomized clinical trial | 2018 | JAMA | Primary |
| EAIF | Effects of the CETP Inhibitor Evacetrapib Administered asMonotherapy or inCombination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial | 2011 | JAMA | Primary |
| CARAT | Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial | 2018 | JAMA | Primary |
Diabetes
| ALECARDIO | Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial | 2014 | JAMA | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes | 2012 | NEJM | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes | 2014 | NEJM | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes | 2017 | NEJM | Primary |
| Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes | 2013 | Diabetes Care | Secondary | |
| Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy | 2013 | Int J Obesity | Secondary | |
| Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes | 2015 | Diabetes Care | Secondary | |
| Two‐year outcomes on bone density and fracture incidence in patients with T2DM randomized to bariatric surgery versus intensive medical therapy | 2015 | Obesity | Secondary | |
| Impact of Weight Loss Trajectory Following Randomization to Bariatric Surgery on Long-Term Diabetes Glycemic and Cardiometabolic Parameters | 2019 | Endocrine Practice | Secondary |
Heart Failure
| ASCEND-HF | Effect of Nesiritide in Patients with Acute Decompensated Heart Failure | 2011 | NEJM | Primary |
| VALOR-HCM | Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy | 2022 | JACC | Primary |
Device
| WRAP-IT | Antibacterial Envelope to Prevent Cardiac Implantable Device Infection | 2019 | NEJM | Primary |
| PARTNER 2A | Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER 2A | 2017 | ATS | Primary |
| The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA | 2018 | EHJ | Secondary | |
| Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial | 2018 | JACC | Secondary | |
| Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis | 2016 | Lancet | Secondary | |
| Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Results From the PARTNER 2 Trial | 2018 | CIRC | Secondary | |
| Inter- and intrasite variability of mortality and stroke for sites performing both surgical and transcatheter aortic valve replacement for aortic valve stenosis in intermediate-risk patients | 2019 | JTCS | Secondary |
Acute Myocardial Infarction
| PROTECTION AMI | Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial | 2014 | EHJ | Primary |
| Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction | 2015 | AHJ | Secondary | |
| AEGIS-1 | Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) | 2016 | Circulation | Primary |
